EyeCon 2024: Bringing innovation from the conference floor to your practice

Commentary
Video

At this year’s EyeCon, Dr. Adam Ramsey shared his passion for integrating the latest advancements in optometry into practice.

Adam Ramsey, OD, owner of Socialite Vision in Palm Beach Gardens, Florida, shared his excitement at the 2024 EyeCon conference in Fort Lauderdale, Florida, an event that he has been a part of since its inception. With a focus on innovation in eye care, Ramsey's presentations are highly anticipated, as he continually seeks to bring the latest advancements to his practice and the broader optometry community.

During his engaging talk, Ramsey emphasized the importance of staying ahead in a rapidly evolving field. "I spend the year looking for new innovations in practice," he stated, highlighting his commitment to integrating cutting-edge products and services into his clinic. This dedication not only enhances patient care but also enriches the learning experience for fellow practitioners attending the conference.

Ramsey's presentation promised to unveil new content that had not been shared previously, encouraging attendees to stay until the end. His enthusiasm for the latest drugs, products, and equipment was palpable, reflecting the dynamic nature of optometry today. "There's always new things to learn about," he remarked, underscoring the profession's commitment to ongoing education and improvement.

A notable highlight of this year’s conference was Ramsey’s collaboration with Jade Coats, OD, who joined him as a partner in sharing valuable insights. Their teamwork exemplified the spirit of knowledge-sharing that characterizes EyeCon, making the event not just a conference, but a community of like-minded professionals eager to advance their practices.

Ramsey's call to action for fellow attendees was clear: to embrace the wealth of information available and integrate new strategies into their practices. With the promise of innovative ideas and practical applications, he aims to empower his peers to enhance patient outcomes and optimize practice management.

As EyeCon continues to be a platform for innovation in eye care, the contributions of dedicated professionals like Ramsey and Coats are instrumental in shaping the future of the industry. Their insights serve as a reminder that staying informed and adaptable is key to thriving in this ever-evolving field.

Recent Videos
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.